A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPGOMEZ, H.NECIOSUP, S.TOSELLO, C.MANO, M.BINES, J.ISMAEL, G.SANTI, P. X.PINCZOWSKY, H.NERON, Y.FANELLI, M.FEIN, L.SAMPAIO, C.LERZO, G.CAPO, A.ZARBA, J. J.BLAJMAN, C.VARELA, M. S.MARTINEZ-MESA, J.WERUTSKY, G.BARRIOS, C. H.2015-11-112015-11-112013CANCER RESEARCH, v.73, suppl.24, 20130008-5472https://observatorio.fm.usp.br/handle/OPI/12116engrestrictedAccessA phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)conferenceObjectCopyright AMER ASSOC CANCER RESEARCH10.1158/0008-5472.SABCSI3-P4-12-26Oncology1538-7445